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Despite successful mass vaccination programs, whooping cough remains a significant cause of neonatal
mortality. Immunity induced by current vaccines wanes in adolescence, requiring additional immunizations to
prevent resurgence. There is a need for a new generation of vaccines capable of conferring long-lasting
immunity from birth. Recently, a live, attenuated whooping cough vaccine, BPZE1, has been developed. Here,
an established murine immunization model was used to examine the induction and longevity of immunological
memory. In this predictive model, BPZE1 conferred a level of protection against virulent bacterial challenge
comparable to that conferred by recovery from prior infection, up to 1 year after immunization. One year after
immunization with BPZE1, a pertussis-specific persistent response, with high levels of gamma interferon
(IFN-), could be detected from spleen cells restimulated with inactivated Bordetella pertussis. BPZE1 induced
low levels of interleukin-17 (IL-17) and no IL-10 or IL-5. BPZE1 immunization induced long-lasting, efficacious
memory B-cell and specific antibody responses dominated by IgG2a, which were boosted by subsequent
challenge. Finally, the antibody induced by BPZE1 was functionally relevant and could clear a virulent B.
pertussis infection in antibody-deficient mice following passive transfer. This study suggests that BPZE1 is
capable of conferring a high level of long-lived effective protection against virulent B. pertussis.
Bordetella pertussis is a Gram-negative pathogenic bacterium
that is the causative agent of whooping cough, a disease that
remains a significant cause of neonatal and infant morbidity
and mortality. Whooping cough results in 300,000 deaths an-
nually, with debilitated lung function, bronchiectasis, febrile
convulsions, and neurological sequelae associated with infec-
tion (7, 47). The current prevalence of disease is remarkable
considering the incorporation of pertussis vaccines into mass
immunization programs (9). The survival of natural infection
by B. pertussis is associated with long-lived and efficacious
immunity (12, 46), and recent analyses suggest that such im-
munity persists for more than 30 years in humans (45). Whole-
cell B. pertussis vaccines (Pw) developed in the 1940s confer
highly effective immunity, but public acceptance has been poor
due to reports of a suboptimal reactogenicity profile (2, 8).
These issues led to the development of acellular B. pertussis
vaccines (Pa) consisting of recombinant, detoxified, purified
virulence factors of B. pertussis and usually are formulated with
tetanus and diphtheria toxoids (DTaP) and other antigens.
It is now clear, from mass immunization campaigns, that
immunity conferred by Pa is less persistent than that induced
by Pw (17) or immunity induced by natural infection (12, 46).
Pa-induced immunity wanes during a 10- to 15-year period
(36), an observation that has necessitated the introduction of
booster immunization in adolescents to prevent the establish-
ment of an adolescent reservoir of infection (9). When this
situation is accompanied by the late conferral of protection (6
months) imposed by the requirement for three infant doses, a
situation is created that allows the transmission of B. pertussis
to an unprotected and highly susceptible infant population.
This may explain the intransigence of whooping cough as a
public health crisis despite the development of effective vac-
cines (9).
Immunity to B. pertussis is complex. While single correlates
of protection have been proposed (42, 43), protective immu-
nity requires both a strong cellular and antibody response (22).
The reasons for this are open to debate but appear to go
beyond the contribution of CD4 populations to the antibody
response (22, 25). Pw and Pa appear to protect through slightly
different mechanisms, with Pw or natural infection inducing
Th1 or Th1/Th17 type responses, respectively, whereas Pa typ-
ically induce more Th2-like immunity in humans (39, 40). It
has been suggested that CD4 populations and, in particular,
Th1 cells contribute directly to the elimination of bacteria (25,
34). This has been clarified by mechanistic studies demonstrat-
ing that intracellular B. pertussis corrupts the sentinel functions
of macrophages and dendritic cells (5), and that gamma inter-
feron (IFN-) counters this effect, supporting earlier observa-
tions that IFN- responses were beneficial to the protective
response against B. pertussis (25, 26).
The requirements for improved neonatal protection and
more persistent long-term immunity (15, 28) have led to the
development of a live, attenuated B. pertussis candidate vac-
cine, BPZE1, which is appropriate for single neonatal immu-
nization (30). BPZE1 retains the capacity to colonize but lacks
pathogenicity through the attenuation of the B. pertussis viru-
lence factors pertussis toxin (PT), dermonecrotic toxin (DNT),
and tracheal cytotoxin (TCT). Here, PT has been genetically
attenuated to ablate the classical enzymatic activity while re-
maining highly immunogenic (30). This was achieved by two
alterations, at Arg-9 to Lys and Glu-129 to Gly, in subunit 1 to
render PT enzymatically inactive. In BPZE1 the DNT gene has
been completely deleted, while TCT has been attenuated by
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the transgenic expression of the Escherichia coli transporter
protein AmpG, which restored regular peptidoglycan metabo-
lism with a consequent loss of TCT production. Previously, we
and others have shown BPZE1 to be safe and efficacious in
adult and neonate animal models, including immunocompro-
mised mice (41). Consequently, BPZE1 is a candidate for
phase I human clinical trials. However, the nature and persis-
tence of long-term immunity following BPZE1 immunization
has yet to be characterized.
There is a long tradition of using murine models in support
of pertussis vaccine development (20). Here, an established
murine aerosol challenge model of B. pertussis immunization
that correlates with vaccine performance in human clinical
trials (33, 35) was used to examine the induction of immuno-
logical memory and the persistence of protection. Serum an-
tibody responses and the profile of cell-mediated immunity to
BPZE1 were investigated at extended periods after immuni-
zation. BPZE1 induced Th1 responses and functionally effec-
tive antibody. It primed immune memory and conferred long-
lasting protection. This study suggests that BPZE1 offers a
viable alternative to acellular pertussis immunization. It con-
fers a level of protection comparable to that of previous expo-
sure to virulent B. pertussis, supporting the translation of
BPZE1 to human trials.
MATERIALS AND METHODS
Mice. Adult female (6- to 8-week-old) BALB/c, C57BL/6, or MT mice were
used under the guidelines of the Irish Department of Health, and all procedures
were approved by the research ethics committee of the National University of
Ireland Maynooth.
B. pertussis strains and growth conditions. B. pertussis Tohama I derivatives
BPSM and BPZE1 have been described previously (29, 30). In BPZE1, the
expression of other virulence factors, such as filamentous hemagglutinin (FHA),
adenylate cyclise-hemolysin (ACT), or pertactin (PRN), was not significantly
different from that of the parental strain (C. Locht, personal communication). B.
pertussis strains were grown at 37°C for 48 to 72 h on Bordet-Gengou agar
(Gibco) supplemented with 15% defibrinated horse blood. Colonies then were
transferred to Stainer and Scholte liquid medium containing streptomycin (30
g/ml). Cultures were grown to mid-log phase and were maintained carefully to
prevent phase modulation.
Aerosol infection. Respiratory infection was initiated by aerosol infection with
the various B. pertussis strains according to established protocols (26). Bacteria
from mid-log-phase cultures (2  1010 CFU/ml) were delivered by nebulizer,
during a 20-min period, to mice housed in an exposure chamber such that a
colonization of between 5 to 7  105 CFU/lung was achieved. This dose was
chosen for consistency with previous reports using this system (26) and with
previous studies examining the effect of dose on the aerosol challenge model (4).
Control mice were challenged with a sham aerosol of 1% (wt/vol) casein solution
in sterile physiological saline. For long-term cytokine and antibody studies, sera
or spleens were harvested 1 year postinfection.
Antibody passive transfer studies. C57BL/6 mice were challenged, as de-
scribed above, via aerosol with BPZE1. On day 40 postinfection, whole blood was
collected from the submandibular vein (BD Biosciences, Oxford, United King-
dom). Whole blood was allowed to clot and then was centrifuged for 5 min at
900 g, and serum was removed. B-cell-deficient MT mice were challenged via
aerosol with virulent BPSM. On days 7 and 42 postinfection, MT mice received
50 l of serum intravenously (i.v.) (via the tail vein) as previously described (35),
and the bacterial burden was monitored.
Determination of B. pertussis-specific antibody. Endpoint titers of B. pertussis-
specific antibody were measured from murine sera in a 96-well plate format (4).
Enzyme-linked immunosorbent assay (ELISA) plates (Nunc, Roskilde, Den-
mark) were coated overnight with heat-inactivated virulent B. pertussis. This was
selected as the antigen mixture to be consistent with previous studies and to allow
the assessment of the immune response directed against whole virulent bacteria
(as in exposure) and not simply that against selected virulence factors. Plates
then were blocked and washed before incubation with 10-fold dilutions of murine
sera. Following 2 h of incubation and washing, biotinylated IgG, IgG1, IgG2a,
IgG2b, or IgG3 detection antibody (BD, Oxford, England) was added for 1 h
before repeat washes and the addition of streptavidin-horseradish peroxidase
(HRP) (GE Healthcare, Uppsala, Sweden). Following a 30-min incubation,
plates were washed and IgG binding detected by the HRP substrate TMB
(Sigma-Aldrich, Wicklow, Ireland), and the reaction was stopped using 1 M
H2SO4. Absorbance was measured at 450 nm. The endpoint titer was calculated
as the dilution at which the regression line of absorbance intersected a line 2
standard deviations greater than the threshold generated by control naïve sam-
ples (16). All detection reagents used in this study had been previously optimized
and validated.
Measurement of IgG B cells by ELISpot assay. Enzyme-linked immunospot
(ELISpot) assay was used to detect the number of IgG B cells in murine spleen
homogenates. A multiscreen HA 96-well plate (Millipore, Cork, Ireland) was
coated with heat-inactivated B. pertussis overnight at 4°C. Following incubation,
plates were washed with sterile phosphate-buffered saline (PBS) and blocked
with complete RPMI medium for 1 h before the addition of diluted splenocytes
and incubation at 37°C in a 5% CO2 atmosphere for 24 h. Following incubation,
cells were removed, the plate was washed gently in PBS, and B. pertussis-specific
IgG-positive cells were detected by incubation with 1 g/ml biotinylated anti-
mouse IgG antibody (Biosera, Sussex, England) using streptavidin-HRP and
TMB substrate. Color development was stopped by extensive washing with tap
water, the plate then was left to air dry, and the total spot count was determined
by microscopy under 10 magnification. Controls included similar preparations
from age-matched naïve mice.
Cytokine measurement. Cytokine concentrations were determined by a mul-
tiplexed bead array (FlowCytomix, Bender MedSystems, Vienna, Austria) ac-
cording to the manufacturer’s instructions. Briefly, cytokine standards, buffer
control, or sample were added to beads coated with analyte-specific antibodies
with a biotin-conjugated antibody mix and incubated for 2 h in the dark at room
temperature. Following incubation, 1 ml 1% (vol/vol) bovine serum albumin
(BSA)-PBS buffer was added to each tube, and the beads were centrifuged at
200  g for 5 min. Following centrifugation, supernatant was discarded, leaving
100 l, and streptavidin-phycoerythrin was added to each tube before 1 h of
incubation at room temperature. After this incubation, beads were washed twice
in fluorescence-activated cell sorting (FACS) buffer and centrifuged as described
above. Beads then were resuspended in 1 ml buffer, and cytokine concentrations
were determined by flow cytometry calibrated against standards of known con-
centrations.
Statistical methods. All results are expressed as the means  standard errors
of the means (SEM). A Student’s t test was used to determine significance
between the groups. A value of P 0.05 was considered significant. Analyses and
graphical representations were performed using Graph-Pad Prism software
(Graphpad, San Diego, CA).
RESULTS
A live, attenuated pertussis vaccine, BPZE1, confers long-
term immune protection in a predictive murine model. The
murine respiratory aerosol challenge model of protection (26,
35) was used to examine the ability of a live, attenuated vaccine
candidate, BPZE1, to confer long-lasting immunity against
virulent B. pertussis. The aerosol challenge model not only
closely mimics natural infection, but protection induced by
aerosol challenge in mice previously has correlated strongly
with estimated vaccine efficacy in infants (33, 35). Mice were
challenged, by aerosol, with attenuated BPZE1, virulent B.
pertussis BPSM, or a sham inoculum of 1% casein (wt/vol) in
PBS, and they were housed long term under isolator condi-
tions. One year postchallenge, mice received an aerosol chal-
lenge of virulent B. pertussis BPSM. Lungs were harvested and
bacterial loads determined at days 0, 7, 10, and 14 postinfec-
tion. Naive mice showed a typical course of primary infection
and had no protection against virulent B. pertussis infection
(Fig. 1). These data also indicated that the potential immuno-
logical experience of the mice regarding environmental antigen
in the year between setup and challenge did not confer any
cross-protection. As previously demonstrated, there was a sig-
nificant reduction in bacterial carriage in the lungs of mice
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previously challenged with virulent B. pertussis BPSM (Fig. 1).
This was evidenced by a significant reduction of bacterial bur-
den at days 7 (P  0.0001), 10 (P  0.0001), and 14 (P 
0.0001) and confirmed the capacity of prior B. pertussis infec-
tion to induce long-term protection. Mice immunized with live,
attenuated BPZE1 were protected 1 year after immunization
(Fig. 1). These mice showed reduced bacterial burden com-
pared to that of naive mice and a level of protection not
significantly different from that observed following prior viru-
lent BPSM exposure at day 7 (P  0.0605), 10 (P  0.2099), or
14 (P  0.5734) postinfection. Thus, live, attenuated BPZE1
confers long-term protection at least comparable to that in-
duced by virulent challenge.
Immunization with BPZE1 induces a pertussis-specific per-
sistent Th1 response. Previous reports had suggested that Th1-
associated cytokines were beneficial for the optimal clearance
of and protection against B. pertussis (4, 25, 40). However, to
date, nothing is known about the nature of the long-term
cytokine response following BPZE1 vaccination. To examine
the nature of the memory response, mice were challenged, as
described above, with either BPSM or BPZE1 and then chal-
lenged 1 year later with virulent BPSM. Splenocytes from be-
fore and after the second challenge were harvested from
groups of mice, and IFN-, IL-5, IL-10, and IL-17 recall re-
sponses to inactivated B. pertussis were measured.
Prior to a secondary virulent challenge, control mice showed
no B. pertussis-specific cell-mediated immunity, as expected
(Fig. 2). Virulent BPSM or attenuated BPZE1 challenge in-
duced strong B. pertussis-specific IFN- recall responses but
little or no IL-5 response, indicating the induction and persis-
tence of a strong Th1 response (Fig. 2A and B). However,
recall in these mice was not immunologically identical; mice
exposed to virulent B. pertussis displayed high IL-17 responses
to antigen restimulation, whereas BPZE1 priming resulted in
detectable but significantly lower (P  0.0036) IL-17 re-
sponses, suggesting that the attenuation to BPZE1 directly or
indirectly (41) altered the ability to induce a Th17 response.
Negligible IL-10 was induced by either BPSM or BPZE1.
Primed animals also were rechallenged after 1 year by aero-
FIG. 1. BPZE1 induced long-term protection against virulent B.
pertussis. Mice were challenged or immunized with virulent BPSM
(triangles), attenuated BPZE1 (circles), or a sham immunization con-
trol (squares). One year later, mice were challenged with virulent
BPSM. Results are representative of two experiments expressed as
mean (SEM) CFU per lung detected in triplicate from five mice per
group at each time point. Error bars that are not visible are masked by
the data point symbol.
FIG. 2. BPZE1-primed mice developed a long-lived cell-mediated immune response with a cytokine profile comparable to that of virulent
challenge. Mice were primed by BPZE1 immunization or BPSM challenge. One year later, primed mice were challenged with a casein control (),
virulent BPSM, or attenuated BPZE1. Splenocytes were harvested and restimulated in vitro with heat-inactivated BPSM (closed) or medium
control (open bars). Splenocytes from naive mice failed to respond to antigens at levels above those in medium controls (data not shown). Results
are expressed as mean (SEM) analyte concentrations (in pg/ml) (n  5) from triplicate determinations.
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sol with either virulent BPSM or BPZE1 to examine the an-
amnestic response. BPSM-primed and -rechallenged mice pro-
duced elevated IFN- (Fig. 2A) and IL-17 (Fig. 2B) but not
IL-5 (Fig. 2C) or IL-10 (Fig. 2D) in response to in vitro re-
stimulation by B. pertussis. A second challenge with BPZE1, 1
year after the initial priming, resulted in boosted IFN- (Fig.
2A) but not IL-5 (Fig. 2C), IL-17 (P  0.1079), or IL-10 (P 
0.0571) response.
Mice primed by BPZE1 and then rechallenged 1 year later
by BPSM (a situation analogous to immunization and expo-
sure) showed boosted IFN- responses but no IL-5 or IL-10
response, demonstrating the persistence of the initial Th1-like
phenotype (Fig. 2). IL-17 levels were significantly enhanced
only when mice were exposed to virulent BPSM, not BPZE1,
and this was similar to the primary Th17 response evoked by
BPSM. Thus, BPZE1 induced a stable, long-lasting Th1-like
immunity and primed IL-17 responses in animals exposed to
virulent bacteria.
BPZE1 immunization induced long-lasting, efficacious B-
cell and antibody responses. Murine models have been used
extensively to probe the longevity of the vaccine-induced im-
munity to B. pertussis (20, 32, 33, 35). To characterize the
nature and longevity of the antibody response to BPZE1 im-
munization, sera and splenic B-cell responses were examined
from long-term-immunized mice. Antibody responses to heat-
inactivated B. pertussis were measured in an attempt to mea-
sure the total immune response directed against whole virulent
bacteria (as in exposure) and not simply that against selected
virulence factors; parallel studies have been performed using
single antigens to compare the BPZE1 response to that of
acellular vaccines (14). B. pertussis-specific IgG memory B
cells were quantified by ELISpot assay, and the titer of anti-
body responses were quantitatively and qualitatively character-
ized. High serum levels of specific IgG were found 1 year after
BPSM or BPZE1 priming, with no antibody detected in control
animals (Fig. 3A). A boost in IgG was noted following a second
challenge with virulent BPSM. Thus, BPZE1 induced long-
lasting antibody responses to virulent BPSM, but intriguingly,
IgG responses to BPSM were significantly higher (P  0.0128)
in BPZE1-primed mice than in BPSM-primed mice (Fig. 3),
supporting previous data suggesting that during natural infec-
tion by virulent B. pertussis virulence, factors such as PT and
DNT suppress adaptive immunity (19). Both virulent BPSM
and attenuated BPZE1 resulted in murine antibody responses
dominated by IgG2a (Table 1), mirroring the induction of
IFN- seen in Fig. 2. No B. pertussis-specific IgE was detected
following BPZE1 immunization.
Antibody titer is only one index of the persistence of mem-
ory, and indeed the presence of memory B cells may be more
important in vaccine-induced immunity. ELISpot therefore
was used to measure pertussis-specific IgG memory B cells
from the spleens of long-term-challenged mice. Both BPSM
challenge and BPZE1 vaccination induced high numbers of
IgG memory B cells (Fig. 3). No significant difference (P 
0.4918) was seen between mice that received BPZE1 or those
that received virulent BPSM (Fig. 3B). Taken together, these
results demonstrated that BPZE1 induced a long-lasting mem-
ory B-cell response and corresponding specific antibody similar
or superior in both quality and quantity to that induced by
virulent infection.
Antibody induced by BPZE1 can clear virulent B. pertussis
following passive transfer. Antibody titers determined by
ELISA or cellular responses by ELISpot do not indicate the
quality of the antibody response and, in particular, do not
predict whether the antibody is functionally relevant or neu-
tralizing. It has been shown previously that antibody, passively
transferred from mice vaccinated with whole-cell or acellular
vaccines, is capable of reducing bacterial loads in infected mice
lacking conventional Ig responses (35). To determine whether
BPZE1-induced antibody was functionally effective against vir-
ulent B. pertussis, MT mice, which lack functional antibody
FIG. 3. BPZE1 challenge induced a long-term specific antibody
response comparable to that of virulent challenge. (A) B. pertussis-
specific serum IgG levels were measured 1 year after BPSM or BPZE1
priming and again following virulent BPSM challenge by ELISA using
heat-inactivated whole bacteria as the antigen. Results are expressed
as mean (SEM) endpoint titers (n  5 for triplicate determinations).
(B) Splenocytes were isolated from BPZE1, BPSM, or sham-chal-
lenged naive mice 1 year postpriming to measure the induction of
long-term B. pertussis-specific IgG memory B cells by ELISpot. Re-
sults are expressed as mean antibody-forming cells per 106 splenocytes
for triplicate determinations.
TABLE 1. B. pertussis-specific IgG induced by priming
and/or challenge
Prime/challenge
Antibody titera
Naı¨ve BPSM BPZE1 BPSM-BPSM BPZE1-BPSM
IgG1 1/10 1/250 1/500 1/1,000 1/1,000
IgG2a 1/10 1/7,500 1/6,000 1/20,000 1/50,000
IgG2b 1/10 1/500 1/200 1/5,000 1/5,000
IgG3 1/10 1/1,000 1/1,000 1/2,000 1/500
a IgG subclass endpoint titers were determined 1 year following the aerosol
administration of 1% casein (wt/vol) (naı¨ve), virulent BPSM, or vaccine strain
BPZE1. To determine if primed mice experienced boosted antibody levels fol-
lowing repeat exposure, serum antibody levels were measured from mice primed
with BPSM (BPSM-BPSM) or BPZE1 (BPZE1-BPSM) who received a second
BPSM challenge 1 year following priming. Results are expressed as mean end-
point titers (n  5).
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(21), were challenged with BPSM. At days 7 and 21 postinfec-
tion, mice were intravenously injected with sterile PBS or di-
luted sera raised against BPZE1.
A chronic persistent infection was observed in the control
MT mice, which is consistent with previous findings (26)
showing antibody to be essential for sterilizing protection
against B. pertussis (Fig. 4). Mice that received passive immu-
nization with serum from BPZE1-challenged mice successfully
cleared infection. Following the initial passive transfer, serum-
treated mice exhibited reductions of approximately 2 log in
bacterial load. Complete clearance subsequently was observed
following a second passive transfer to these mice (Fig. 4).
These findings indicate that antibody evoked by BPZE1 im-
munization is functional against virulent B. pertussis and af-
fords protection against virulent bacteria.
DISCUSSION
This study examines the longevity of protection induced by
the live, attenuated candidate vaccine BPZE1. In prime-boost
experiments, BPZE1 primed long-lasting B. pertussis-specific
IgG responses. This antibody response was accompanied by
strong antigen-specific IFN- responses from restimulated
splenocyte cultures. Such antibody was predominantly of the
IgG2a subclass and conferred protection by passive transfer to
infected immunodeficient mice. Taken together, these data
confirm that BPZE1 conferred a long-lasting protective im-
mune response against virulent B. pertussis challenge.
Immunity to Pa vaccines wanes in adolescence (15, 36).
While infection in adolescents and adults often results in
asymptomatic infection (37), these populations serve as a res-
ervoir for infection, increasing the potential transmission of
the disease to neonates and infants (15). When Pa coverage is
persistently high in adolescent populations, herd immunity
controls the disease (6). These observations highlight three
issues: the importance of vaccine coverage of the target pop-
ulations, the need for B. pertussis vaccines that are capable of
conferring long-term protection, and the desirability of pertus-
sis vaccines suitable for neonates. While neither vaccine- nor
infection-induced immunity to B. pertussis can be said to be life
long, immunity conferred by infection has been estimated to
last at least 20 years, whereas Pa-induced immunity may wane
after 12 years in humans, although little difference is seen
between two- and three-component Pa in the longer term (45,
46). The long-term protection afforded by BPZE1 will require
human clinical trials; nevertheless, this study demonstrated
that BPZE1 could induce long-term protection in a murine
model comparable to prior virulent infection. In very recent
parallel studies, the longevity of the BPZE1-induced protec-
tion by aerosol challenge (herein) was similar to that seen in
the alternative intranasal delivery model (14), where BPZE1
was shown to confer significantly better protection against vir-
ulent challenge than Pa at 9 and 12 months postvaccination.
However, further studies directly comparing the efficacies of
BPZE1 and Pa in this model are required. The virulent infec-
tion of mice and humans induces either Th1 or mixed Th1/
Th17 responses (40), whereas Pw induces Th1 immunity (12,
38, 40). In contrast, a less polarized or even a Th2-dominant
response has been noted when Pa has been employed (23, 39).
Previously, the induction of a Th1 response has been associ-
ated with optimal immunity against pertussis (40), and subop-
timal Pa can be improved when IL-12 is used as an adjuvant in
mice (23). BPZE1 induces strong IFN- responses that are
detectable 1 year after priming. There has been speculation as
to why IFN- has a role in the containment and clearance of B.
pertussis (3, 22). This may be related to observations showing
that virulent B. pertussis subverts sentinel antigen-presenting
cell functions (5). Immunization with attenuated BPZE1 (or
challenge with BPSM) resulted in high levels of IFN- but low
levels of IL-5. This is in keeping with previous reports of the
immunity induced by virulent infection (32, 46) and Pw immu-
nization (40). IL-17 was induced by BPZE1 but was more
evident following BPSM infection. This suggests that the pres-
ence of PT, DNT, and/or TCT contributes to IL-17 induction
in natural infection. Enzymatically active pertussis toxin in-
duces the production of IL-17 (1), and so, reduced IL-17 re-
sponses to BPZE1 could be a product of PT attenuation. Re-
cently, Th17 responses to B. pertussis have been linked to
adenylate cyclase (CyaA) (11). As CyaA is fully functional in
both BPSM and BPZE1, our results suggest redundancy in this
system, possibly linked to intracellular cyclic AMP. A second
challenge with virulent BPSM resulted in a Th1/Th17 response
regardless of the priming antigen. Overall, a key finding of this
study is that BPZE1 primes a persistent cell-mediated immune
response against B. pertussis. The Th1/Th17 profile induced by
BPZE1 may be important in the neonatal context, as Th1
responses typically are weak in human neonates (27, 44) and
during early life (10). In terms of pertussis immunity, priming
this type of response can support long-lived memory and pro-
tection even when antibody responses have waned (24).
While cell-mediated responses are important in vaccine-in-
duced immunity to B. pertussis, the antibody response induced
by immunization is central to clearance and protection (26,
35). BPZE1 induced a long-lived memory B-cell response, as
evidenced by ELISpot assay, and long-lasting, high-titer anti-
body that is detectable in serum. Patterns of IgG subclass
induction in mice are not predictive of human immunity, and
indeed there is little evidence to suggest that various patterns
FIG. 4. BPZE1-induced antibody is functionally effective against
virulent B. pertussis. To assess the functional efficacy of antibody in-
duced by BPZE1 vaccination, MT mice were challenged with virulent
BPSM. At days 7 and 28 postinfection, mice received the passive
transfer of different sera by i.v. injection. Sera were derived from
control naïve mice (closed squares) or from mice immunized by atten-
uated BPZE1 (open squares). Results are expressed as mean (SEM)
CFU per lung, detected in triplicate from five mice per group per time
point. Error bars that are not visible are masked by the data point
symbol.
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of human IgG have any influence on pertussis immunity. How-
ever, this study showed that the antibody evoked by BPZE1
was effective at neutralizing virulent infection in vivo and to
passively confer sterilizing immunity. Thus, BPZE1 promotes
an antibody response of functional efficacy. It is important that
no B. pertussis-specific IgE was detected following BPZE1 im-
munization in this study, in line with recent data showing that
BPZE1 had a pronounced antiatopic effect in murine allergy
models (19). This study also made an intriguing observation of
increased antibody production following challenge with
BPZE1 compared to that with the virulent strain BPSM. Pre-
viously, a B. pertussis strain lacking functional PT was shown to
induce higher antibody levels in mice than wild-type strains
(30), indicating that our findings are associated with the atten-
uation of an immunosuppressive effect of PT.
Defining correlates of protection against B. pertussis has
been notoriously difficult. However, priming immunological
memory is, undoubtedly, a key aspect in the induction of pro-
tection through pertussis immunization. In this regard, the
ELISpot data here are important, as BPZE1 not only evokes
persistent antibody responses but also induces strong immu-
nological priming in the B-cell compartment (Fig. 3), which is
boosted on encounter with virulent bacteria. Previous preclin-
ical studies have shown that BPZE1 is genetically stable (13,
31), safe in neonatal and immunocompromised mouse models
(41), and a feasible vehicle for vaccination with heterologous
antigens (18). This study demonstrates that live, attenuated
BPZE1 confers protection against virulent B. pertussis chal-
lenge, consisting of a Th1 memory response, high-titer B. per-
tussis-specific serum antibody, and the priming of a pertussis-
specific memory B-cell response that persists 1 year following
vaccination. Taken together, these data strongly suggest that
BPZE1 is a viable candidate for translation to human use as a
novel live, attenuated pertussis vaccine.
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